---
title: Daratumumab and antineoplastic therapy versus antineoplastic therapy only for
  adults with newly diagnosed multiple myeloma ineligible for transplant
date: '2024-05-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38695605/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240502181207&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Multiple myeloma (MM) is a haematological malignancy that
  is characterised by proliferation of malignant plasma cells in the bone marrow.
  For adults ineligible to receive high-dose chemotherapy and autologous stem cell
  transplant, the recommended treatment combinations in first-line therapy generally
  consist of combinations of alkylating agents, immunomodulatory drugs, and proteasome
  inhibitors. Daratumumab is a CD38-targeting, human IgG1k monoclonal antibody recently
  developed ...'
disable_comments: true
---
BACKGROUND: Multiple myeloma (MM) is a haematological malignancy that is characterised by proliferation of malignant plasma cells in the bone marrow. For adults ineligible to receive high-dose chemotherapy and autologous stem cell transplant, the recommended treatment combinations in first-line therapy generally consist of combinations of alkylating agents, immunomodulatory drugs, and proteasome inhibitors. Daratumumab is a CD38-targeting, human IgG1k monoclonal antibody recently developed ...